Literature DB >> 15710359

Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression.

Gregory Hans1, Sabine Wislet-Gendebien, François Lallemend, Pierre Robe, Bernard Rogister, Shibeshih Belachew, Laurent Nguyen, Brigitte Malgrange, Gustave Moonen, Jean-Michel Rigo.   

Abstract

Some synthetic ligands of the peripheral-type benzodiazepine receptor (PBR), an 18 kDa protein of the outer mitochondrial membrane, are cytotoxic for several tumor cell lines and arise as promising chemotherapeutic candidates. However, conflicting results were reported regarding the actual effect of these drugs on cellular survival ranging from protection to toxicity. Moreover, the concentrations needed to observe such a toxicity were usually high, far above the affinity range for their receptor, hence questioning its specificity. In the present study, we have shown that micromolar concentrations of FGIN-1-27 and Ro 5-4864, two chemically unrelated PBR ligands are toxic for both PBR-expressing SK-N-BE neuroblastoma cells and PBR-deficient Jurkat lymphoma cells. We have thereby demonstrated that the cytotoxicity of these drugs is unrelated to their PBR-binding activity. Moreover, Ro 5-4864-induced cell death differed strikingly between both cell types, being apoptotic in Jurkat cells while necrotic in SK-N-BE cells. Again, this did not seem to be related to PBR expression since Ro 5-4864-induced death of PBR-transfected Jurkat cells remained apoptotic. Taken together, our results show that PBR is unlikely to mediate all the effects of these PBR ligands. They however confirm that some of these ligands are very effective cytotoxic drugs towards various cancer cells, even for reputed chemoresistant tumors such as neuroblastoma, and, surprisingly, also for PBR-lacking tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710359     DOI: 10.1016/j.bcp.2004.11.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Binding of NIR-conPK and NIR-6T to astrocytomas and microglial cells: evidence for a protein related to TSPO.

Authors:  Michelle Sexton; Grace Woodruff; Eiron Cudaback; Faith R Kreitzer; Cong Xu; Yi Hsing Lin; Thomas Möller; Mingfeng Bai; H Charles Manning; Darryl Bornhop; Nephi Stella
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

Review 2.  Translocator protein-mediated pharmacology of cholesterol transport and steroidogenesis.

Authors:  Vassilios Papadopoulos; Yasaman Aghazadeh; Jinjiang Fan; Enrico Campioli; Barry Zirkin; Andrew Midzak
Journal:  Mol Cell Endocrinol       Date:  2015-03-25       Impact factor: 4.102

Review 3.  Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders.

Authors:  Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

4.  PK11195 effect on steroidogenesis is not mediated through the translocator protein (TSPO).

Authors:  Lan N Tu; Amy H Zhao; Douglas M Stocco; Vimal Selvaraj
Journal:  Endocrinology       Date:  2014-12-23       Impact factor: 4.736

Review 5.  The changing landscape in translocator protein (TSPO) function.

Authors:  Vimal Selvaraj; Douglas M Stocco
Journal:  Trends Endocrinol Metab       Date:  2015-03-21       Impact factor: 12.015

Review 6.  The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection.

Authors:  Paolo Bernardi; Fabio Di Lisa
Journal:  J Mol Cell Cardiol       Date:  2014-09-28       Impact factor: 5.000

7.  PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect.

Authors:  Tiziana Musacchio; Valentino Laquintana; Andrea Latrofa; Giuseppe Trapani; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

8.  The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.

Authors:  Maria C Mendonça-Torres; Stephen S Roberts
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 9.  The mitochondrial death pathway: a promising therapeutic target in diseases.

Authors:  Sanjeev Gupta; George E N Kass; Eva Szegezdi; Bertrand Joseph
Journal:  J Cell Mol Med       Date:  2009-02-09       Impact factor: 5.310

10.  Modulation of intracellular Ca2+ signalling in HeLa cells by the apoptotic cell death enhancer PK11195.

Authors:  Michelangelo Campanella; Gyorgy Szabadkai; Rosario Rizzuto
Journal:  Biochem Pharmacol       Date:  2008-10-04       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.